Twist Bioscience amends bylaws to add proxy access for 3% long-term stockholders

The Bylaws, as amended and restated (the “Restated Bylaws”), were effective immediately and include, among other things, the following changes: · adding a proxy access provision, inserted as new Section 2.13 of Article II of the Restated Bylaws, to allow a stockholder or a group of up to 20 stockholders owning at least 3% of the Company’s outstanding common stock continuously for at least three years to nominate and include in the Company’s proxy statement for an annual meeting director nominees constituting up to the greater of two individuals or 20% of the number of directors in office, provided that the stockholders satisfy the requirements specified in the Restated Bylaws; · eliminating the requirement that the list of stockholders be open to examination at meetings of stockholders to conform to recent amendments to the Delaware General Corporation Law; and · addressing matters relating to Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Universal Proxy Rules